DOCS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Doximity Inc (DOCS) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is facing significant headwinds, including slowing growth, increased competition, insider selling, and negative sentiment from analysts. The lack of positive trading signals and weak financial guidance further support a sell recommendation.
The technical indicators for DOCS suggest a bearish trend. The MACD is above zero but contracting, RSI is neutral at 46.949, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 19.688, and resistance is at 20.98. The stock is range-bound with no clear upward momentum.
The company is investing in AI, which could unlock incremental budget with its new AI Search offering for pharma in the long term.
Analysts have downgraded the stock and lowered price targets significantly, citing slowing growth, increased competition, and weaker-than-expected fiscal 2027 guidance.
Insider selling has increased by 474.47% over the last month.
Pomerantz LLP has initiated an investigation into potential securities fraud claims against the company.
The stock dropped 23% following poor earnings and guidance.
AI investments are compressing margins and affecting profitability.
Doximity's Q4 and fiscal year 2026 earnings report showed revenue guidance of $664 million to $676 million, missing the $687.04 million estimate. The company is facing macroeconomic headwinds and higher AI compute costs, which are pressuring gross margins and near-term profitability.
Analysts have a mixed to negative outlook on DOCS. Barclays downgraded the stock to Equal Weight with a $20 price target, citing slowing growth in the digital advertising space. Other analysts, including Truist, Needham, and Goldman Sachs, have lowered price targets and highlighted concerns about growth deceleration, competition, and weaker fiscal 2027 guidance. While some analysts maintain a Buy or Outperform rating, the overall sentiment is cautious with expectations of prolonged valuation depression.
